VFI supports Sars-Cov-2 vaccine development through GH-VAP (Bill & Melinda Gates Foundation)

VFI is working with grantees from the Bill & Melinda Gates Foundation (BMGF) to evaluate Sars-Cov-2 vaccine candidates. Antigens provided by BMGF grantees are appropriately formulated with adjuvants developed by VFI with the ultimate goal to identify suitable Sars-Cov-2 vaccine candidates which can progress towards the clinic. This work is supported by the Global Health Vaccine Accelerator Platforms (GH-VAP) funded by BMGF.

Share on linkedin
Share on reddit
Share on facebook
Share on twitter
Share on email